A more intelligent approach to prevention

Health science is entering a period defined not merely by treating disease, but by preventing it with greater precision. The latest developments—from malaria vaccination to metabolic medicine—suggest that the next generation of healthcare may be less about one universal solution and more about matching biological tools to specific risks.

The strongest immediate signal comes from PfSPZ-LARC2, a genetically attenuated whole-parasite malaria vaccine. In a Phase 1 trial, 13 of 15 vaccinated participants avoided infection after controlled exposure, compared with none of seven placebo recipients. That represents reported efficacy of 87% against infection.[1] The result is striking, particularly because malaria remains one of the world’s most persistent public-health threats.

Yet this is still early-stage evidence. A small Phase 1 study can demonstrate promise and safety, but it cannot establish how the vaccine will perform across different age groups, parasite strains, transmission settings or health systems. The achievement deserves investment—not premature triumphalism.

What the liver can teach us

A separate clinical trial has placed diet at the centre of the metabolic conversation. Adults with obesity, prediabetes and fatty liver disease who followed a ketogenic diet experienced an average 67% reduction in liver fat over roughly four to five months. Mediterranean and low-fat plant-based diets also reduced liver fat, but by approximately 45%.[2]

The result challenges simplistic arguments about weight loss. Participants in the three groups lost broadly similar amounts of weight, indicating that the composition of a diet may influence liver metabolism independently of the number on the scales. That distinction matters as fatty liver disease becomes increasingly linked to diabetes, cardiovascular disease and other chronic conditions.

However, the findings should not be converted into another dietary slogan. The trial was small, closely supervised and short. Ketogenic diets can be difficult to maintain, and their long-term effects, nutritional adequacy and suitability for people with different medical conditions require further study. Personalised clinical guidance remains more responsible than dietary evangelism.

Beyond appetite suppression

Obesity treatment is also broadening beyond appetite suppression. Researchers at the University of California, Berkeley have identified a compound intended to increase energy expenditure—the body’s ability to burn energy—rather than primarily reducing hunger. This could represent a different therapeutic mechanism from popular medicines such as Ozempic and Wegovy.

That distinction is scientifically important. Appetite-targeting drugs have transformed expectations about obesity care, but they do not eliminate questions about cost, access, side effects, weight regain and the biological diversity of obesity. A medicine that safely increases energy expenditure could eventually expand the range of options available to patients.

Another experimental weight-loss treatment has produced an equally notable finding: relief from knee osteoarthritis pain. At the highest dose, participants lost approximately 25% of their body weight, while around two-thirds achieved at least a 50% reduction in knee pain.[3] The result reflects the close relationship between excess weight, inflammation and mechanical stress on joints—but it should not imply that obesity is simply a matter of personal failure. Effective treatment must be paired with dignity, long-term support and social understanding.

The arms race against resistance

The news is not uniformly optimistic. Researchers have described a bacterial resistance mechanism in which bacteria rapidly close cellular entry channels, limiting the ability of last-resort antibiotics to enter.[4] Such a discovery illustrates the extraordinary adaptability of microbes and the fragility of modern medicine.

Antibiotic resistance cannot be solved by new drugs alone. It requires responsible prescribing, faster diagnostics, infection prevention, surveillance and sustained research funding. Every defensive mechanism identified in bacteria is a reminder that scientific progress is an arms race.

Taken together, these developments offer a balanced lesson. The future of health will be shaped by powerful vaccines, targeted metabolic therapies and increasingly sophisticated biology. But breakthroughs become public-health victories only when they survive rigorous testing, reach the people who need them and are used wisely. Hope is justified. Hype is not.